Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are effective pharmacotherapies for obesity, producing significant weight loss and cardiovascular benefits.
GLP-1 medications like semaglutide are highly effective for weight loss and cardiovascular health. They are a standard treatment for obesity, not a cosmetic fix. Discuss them with your doctor.
StrongSupportsVERY_HIGH confidence
The second-generation medications... are coming closer to bariatric surgery average weight losses with 16%–17% and 19%–20% respectively... The SELECT trial solidifies that the use of semaglutide in those with overweight or obesity should take its place alongside other standard evidence-based practices such as pharmacologic treatment of HTN, diabetes, and dyslipidemia for secondary atherosclerotic cardiovascular disease prevention.
Why this rating
Supported by RCTs (SELECT trial) and expert consensus.
Source
Assessing the state of obesity care: Quality, access, guidelines, and standards
Lee M. Kaplan et al. · Obesity Science & Practice · 2024
DOI 10.1002/osp4.765
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.Strong
- Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and type 2 diabetes, producing superior long-term weight loss and remission rates compared to lifestyle or pharmacologic interventions.Strong
- BMI is an inadequate and potentially harmful sole metric for assessing obesity severity and treatment response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →